| Literature DB >> 29730645 |
Hiroshi Kumagai1,2,3, Toru Yoshikawa4, Kanae Myoenzono5, Keisei Kosaki1,3, Nobuhiko Akazawa1,6, Zempo-Miyaki Asako4, Takehiko Tsujimoto7, Tetsuhiro Kidokoro2, Kiyoji Tanaka1, Seiji Maeda8.
Abstract
BACKGROUND: As arterial stiffness increases in the absence of subjective symptoms, a personal indicator that reflects increased risk of cardiovascular disease is necessary. Penile erection is regulated by vascular function, and atherosclerosis affects the penile artery earlier than it affects the coronary and carotid arteries. Therefore, we hypothesized that deterioration of erectile function could be a marker of increased risk for cardiovascular disease. To test our hypothesis, we assessed erectile function and arterial stiffness in a cross-sectional study. METHODS ANDEntities:
Keywords: arterial stiffness; erectile dysfunction; predictors; sexual dysfunction; vascular function
Mesh:
Year: 2018 PMID: 29730645 PMCID: PMC6015322 DOI: 10.1161/JAHA.117.007964
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Characteristics of Studied Men (n=317)
| Characteristics | Value |
|---|---|
| Age, y | 59±15 |
| Height, cm | 168.0±6.7 |
| Body mass, kg | 67.4±11.7 |
| Body mass index, kg/m2 | 23.8±3.4 |
| Waist circumference, cm | 85.3±10.3 |
| Total cholesterol, mg/dL | 207±36 |
| HDL cholesterol, mg/dL | 61±15 |
| LDL cholesterol, mg/dL | 122±33 |
| Triglycerides, mg/dL | 115±66 |
| Glucose, mg/dL | 103±19 |
| HbA1c, mg/dL | 5.5±0.5 |
| Testosterone, nmol/L | 20.6±6.9 |
| Hemodynamics | |
| Systolic blood pressure, mm Hg | 127±15 |
| Diastolic blood pressure, mm Hg | 79±11 |
| Mean arterial pressure, mm Hg | 99±13 |
| Pulse pressure, mm Hg | 48±9 |
| Heart rate, bpm | 61±10 |
| cfPWV, cm/s | 909±206 |
| baPWV, cm/s | 1466±274 |
| faPWV, cm/s | 957±108 |
| PWV ratio | 0.95±0.21 |
| Male functions | |
| IIEF5 score, points | 17±6 |
| AMS total, points | 29±8 |
| AMS somatic, points | 12±4 |
| AMS psychological, points | 7±2 |
| AMS sexual, points | 11±4 |
| Principal risk factors, n (%) | |
| Hypertension | 116 (36.6) |
| Dyslipidemia | 115 (36.3) |
| Diabetes mellitus | 31 (9.8) |
| Medications, n (%) | |
| Antihypertensive | 80 (25.2) |
| Antihypercholesterolemic | 41 (12.9) |
| Antihyperglycemic | 16 (5.0) |
| Medical history, n (%) | |
| Angina | 9 (2.8) |
| Myocardial infarction | 3 (0.9) |
| Stroke | 7 (2.2) |
| Current smoking, n (%) | 21 (6.6) |
Data are shown as the mean±SD or frequency count (percentage), as appropriate. AMS indicates Aging Males’ Symptoms; baPWV, brachial‐ankle PWV; bpm, beats per minute; cfPWV, carotid‐femoral PWV; faPWV, femoral‐ankle PWV; HbA1c, glycosylated hemoglobin; HDL, high‐density lipoprotein; IIEF5, International Index of Erectile Function 5; LDL, low‐density lipoprotein; and PWV, pulse wave velocity.
Data are available in 304 individuals.
Data are available in 253 individuals.
Figure 1Age‐related differences in the International Index of Erectile Function 5 (IIEF5) scores (A) and the Aging Males’ Symptoms (AMS) sexual scores (B). Data available in 253 individuals in AMS sexual score. Data are expressed as mean±SD. a P<0.05 vs young‐aged group, b P<0.05 vs middle‐aged group.
Figure 2Correlations between the International Index of Erectile Function 5 (IIEF5) scores and carotid‐femoral pulse wave velocity (cfPWV), brachial‐ankle PWV (baPWV), femoral‐ankle PWV (faPWV), and PWV ratio in each age group (young‐aged, n=40; middle‐aged, n=97; older‐aged, n=180).
Figure 3Correlations between the Aging Males’ Symptoms (AMS) sexual scores and carotid‐femoral pulse wave velocity (cfPWV), brachial‐ankle PWV (baPWV), femoral‐ankle PWV (faPWV), and PWV ratio in each age group (young‐aged, n=37; middle‐aged, n=57; older‐aged, n=159).
Independent Correlates of cfPWV, baPWV, faPWV, and PWV Ratio
| Variable | cfPWV ( | baPWV ( | faPWV ( | PWV Ratio ( | ||||
|---|---|---|---|---|---|---|---|---|
| β |
| β |
| β |
| β |
| |
| Age, y | 0.411 | <0.001 | 0.396 | <0.001 | 0.246 | <0.001 | 0.305 | <0.001 |
| Height, cm | 0.173 | <0.001 | −0.097 | 0.027 | 0.019 | 0.727 | 0.174 | 0.003 |
| Waist circumference, cm | −0.127 | 0.013 | −0.061 | 0.190 | 0.024 | 0.681 | −0.157 | 0.012 |
| Systolic blood pressure, mm Hg | 0.213 | <0.001 | 0.373 | <0.001 | 0.431 | <0.001 | 0.003 | 0.965 |
| HDL cholesterol, mg/dL | −0.006 | 0.912 | −0.013 | 0.778 | 0.001 | 0.990 | −0.010 | 0.871 |
| LDL cholesterol, mg/dL | −0.020 | 0.660 | −0.045 | 0.285 | −0.001 | 0.976 | −0.017 | 0.754 |
| Triglycerides, mg/dL | 0.023 | 0.662 | −0.007 | 0.891 | 0.055 | 0.362 | −0.004 | 0.951 |
| Glucose, mg/dL | 0.183 | <0.001 | 0.086 | 0.055 | 0.011 | 0.843 | 0.187 | 0.002 |
| Testosterone, nmol/L | 0.072 | 0.107 | 0.051 | 0.208 | −0.020 | 0.701 | 0.086 | 0.113 |
| Medications | ||||||||
| Antihypertensive, yes/no | 0.158 | 0.001 | 0.165 | <0.001 | 0.120 | 0.031 | 0.108 | 0.064 |
| Antihypercholesterolemic, yes/no | −0.022 | 0.622 | −0.060 | 0.147 | −0.021 | 0.685 | −0.015 | 0.792 |
| Antihyperglycemic, yes/no | −0.001 | 0.988 | 0.016 | 0.718 | −0.020 | 0.722 | 0.008 | 0.898 |
| Medical history | ||||||||
| Angina, yes/no | 0.031 | 0.478 | 0.014 | 0.724 | −0.003 | 0.946 | 0.039 | 0.458 |
| Myocardial infarction, yes/no | −0.027 | 0.524 | −0.043 | 0.264 | −0.101 | 0.039 | 0.025 | 0.623 |
| Stroke, yes/no | −0.039 | 0.362 | 0.051 | 0.192 | 0.050 | 0.313 | −0.064 | 0.224 |
| Current smoking, yes/no | −0.051 | 0.226 | −0.054 | 0.157 | −0.035 | 0.461 | −0.037 | 0.467 |
| IIEF5 score, points | −0.226 | <0.001 | −0.053 | 0.230 | 0.030 | 0.590 | −0.254 | <0.001 |
Covariates included in the multiple linear regression models were age, height, waist circumference, systolic blood pressure, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides, fasting blood glucose, testosterone, antihypertensive medication, antihypercholesterolemic medication, antihyperglycemic medication, medical history of angina, myocardial infarction, and stroke, current smoking, and IIEF5 scores. baPWV indicates brachial‐ankle PWV; cfPWV, carotid‐femoral PWV; faPWV, femoral‐ankle PWV; HDL, high‐density lipoprotein; IIEF5, International Index of Erectile Function 5; LDL, low‐density lipoprotein; and PWV, pulse wave velocity.
Log‐transformed.
Characteristics of Subjects Classified by the Severity of ED
| Characteristics | No ED (IIEF5 Score >21) | Mild ED (IIEF5 Score 17–21) | Mild to Moderate ED (IIEF5 Score 12–16) | Moderate ED (IIEF5 Score 8–11) | Severe ED (IIEF5 Score <8) |
|
|---|---|---|---|---|---|---|
| Number | 85 | 108 | 71 | 21 | 32 | … |
| Age, y | 49±16 | 57±13 | 64±12 | 67±7 | 72±9 | <0.001 |
| Height, cm | 169.7±6.3 | 169.3±6.3 | 165.4±6.9 | 167.5±5.9 | 164.7±6.6 | <0.001 |
| Body mass, kg | 68.2±11.6 | 69.3±12.1 | 65.3±11.1 | 65.9±11.6 | 63.8±11 | 0.080 |
| Body mass index, kg/m2 | 23.7±3.6 | 24.1±3.6 | 23.8±3.2 | 23.4±3.4 | 23.4±3.0 | 0.807 |
| Waist circumference, cm | 84.1±10.5 | 86.5±11.4 | 84.7±8.7 | 86.6±10.4 | 84.7±8.6 | 0.325 |
| Total cholesterol, mg/dL | 203±34 | 209±36 | 208±36 | 216±36 | 207±45 | 0.769 |
| HDL cholesterol, mg/dL | 61±16 | 62±15 | 60±15 | 65±18 | 60±16 | 0.856 |
| LDL cholesterol, mg/dL | 119±31 | 123±33 | 123±36 | 125±25 | 121±35 | 0.915 |
| Triglycerides, mg/dL | 108±59 | 115±67 | 119±78 | 127±67 | 118±54 | 0.533 |
| Glucose, mg/dL | 99±18 | 104±15 | 103±17 | 110±38 | 107±19 | 0.010 |
| HbA1c, mg/dL | 5.4±0.6 | 5.5±0.6 | 5.6±0.5 | 5.7±0.6 | 5.6±0.5 | 0.017 |
| Testosterone, nmol/L | 21.3±7.2 | 20.1±5.2 | 20.6±6.0 | 22.0±9.6 | 19.3±10.0 | 0.479 |
| Hemodynamics | ||||||
| Systolic blood pressure, mm Hg | 124±15 | 128±14 | 126±14 | 129±17 | 135±16 | 0.001 |
| Diastolic blood pressure, mm Hg | 77±12 | 81±10 | 79±9 | 78±11 | 81±10 | 0.129 |
| Mean arterial pressure, mm Hg | 95±13 | 100±12 | 99±11 | 99±13 | 105±13 | 0.001 |
| Pulse pressure, mm Hg | 47±8 | 47±8 | 47±9 | 51±10 | 54±12 | 0.007 |
| Heart rate, bpm | 61±11 | 62±11 | 60±10 | 60±8 | 63±10 | 0.731 |
| baPWV, cm/s | 1359±230 | 1438±251 | 1515±277 | 1529±275 | 1695±295 | <0.001 |
| faPWV, cm/s | 934±111 | 956±109 | 965±97 | 958±84 | 999±123 | 0.059 |
| Principal risk factors, n (%) | 0.556 | |||||
| Hypertension | 18 (21.1) | 42 (38.9) | 26 (36.6) | 7 (33.3) | 23 (71.9) | <0.001 |
| Dyslipidemia | 24 (28.2) | 40 (37.0) | 28 (39.4) | 9 (42.9) | 14 (43.8) | 0.423 |
| Diabetes mellitus | 6 (7.1) | 10 (9.3) | 6 (8.5) | 2 (9.5) | 7 (21.9) | 0.185 |
| Medications, n (%) | ||||||
| Antihypertensive | 11 (12.9) | 28 (25.9) | 20 (28.2) | 5 (23.8) | 16 (50.0) | 0.002 |
| Antihypercholesterolemic | 4 (4.7) | 18 (16.7) | 9 (12.7) | 5 (23.8) | 5 (15.6) | 0.065 |
| Antihyperglycemic | 2 (2.4) | 5 (4.6) | 2 (2.8) | 1 (4.8) | 6 (18.8) | 0.006 |
| Medical history, n (%) | ||||||
| Angina | 3 (3.5) | 2 (1.9) | 3 (4.2) | 0 (0) | 1 (3.1) | 0.801 |
| Myocardial infarction | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) | 2 (6.3) | 0.021 |
| Stroke | 0 (0) | 2 (1.9) | 3 (4.2) | 1 (4.8) | 1 (3.1) | 0.395 |
| Current smoking, n (%) | 6 (7.1) | 4 (3.7) | 7 (9.9) | 2 (9.5) | 2 (6.3) | 0.556 |
Data are shown as the mean±SD or frequency count (percentage), as appropriate. baPWV indicates brachial‐ankle pulse wave velocity; bpm, beats per minute; ED, erectile dysfunction; faPWV, femoral‐ankle pulse wave velocity; HbA1c, glycosylated hemoglobin; HDL, high‐density lipoprotein; IIEF5, International Index of Erectile Function 5; and LDL, low‐density lipoprotein.
Data are available in 304 individuals.
Figure 4Association between severity of erectile dysfunction (ED) classified by International Index of Erectile Function 5 score and carotid‐femoral pulse wave velocity (cfPWV; A) and PWV ratio (B). Data are expressed as mean±SD. a P<0.05 vs no erectile dysfunction, b P<0.05 vs mild ED, c P<0.05 vs mild to moderate ED.